pazopanib (GW786034)
VEG105281
Phase 2 small_molecule completed
Quick answer
pazopanib (GW786034) for Neoplasms, Uterine Cervix is a Phase 2 program (small_molecule) at GlaxoSmithKline with 1 ClinicalTrials.gov record(s).
Program details
- Company
- GlaxoSmithKline
- Indication
- Neoplasms, Uterine Cervix
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed